CAPETTI, AMEDEO FERDINANDO

CAPETTI, AMEDEO FERDINANDO  

Mostra records
Risultati 1 - 20 di 30 (tempo di esecuzione: 0.0 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
Analyzing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicenter cohort of virologically-suppressed PLWHIV 2023 Maria Vittoria CossuAndrea GiacomelliAmedeo CapettiSpinello Antinori + Article (author) -
Concomitant diagnosis of sexually transmitted infections and human monkeypox in patients attending a sexual health clinic in Milan, Italy 2023 Rizzo, AlbertoPozza, GiacomoSalari, FedericaGiacomelli, AndreaMileto, DavideCossu, Maria VittoriaMancon, AlessandroGagliardi, GloriaMicol, BianchiMicheli, ValeriaCapetti, AmedeoAntinori, SpinelloGismondo, Maria RitaLombardi, Alessandra + Article (author) -
Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort 2022 Capetti A.Giacomelli A. + Article (author) -
Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects 2022 Borgonovo, FabioStangalini, Carlo AlbertoMileto, DavideCossu, Maria VittoriaGagliardi, GloriaCutrera, MiriamCapetti, Amedeo F + Article (author) -
Brief Report : Impact of the COVID-19 Pandemic on Virological Suppression in People Living With HIV Attending a Large Italian HIV Clinic 2021 Giacomelli, AndreaBonazzetti, CeciliaConti, FedericoPezzati, LauraMicheli, ValeriaMancon, AlessandroAlbrecht, MariaPasserini, MatteoCossu, Maria VittoriaCapetti, Amedeo FerdinandoAntinori, SpinelloGalli, Massimo + Article (author) -
One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG 2021 Capetti, Amedeo FBorgonovo, FabioMileto, DavideGagliardi, Gloria + Article (author) -
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 2021 Capetti, Amedeo F.Cossu, Maria V.Galli, MassimoGiacomelli, AndreaRusconi, StefanoAliberti, StefanoBlasi, Francesco B.Pilocane, TommasoSimonetta, EdoardoBrunetta, EnricoFolci, MarcoRacca, Francesca + Article (author) -
Is COVID-19 severity associated with anti-spike antibody duration? Data from the ARCOVID prospective observational study 2021 Passerini, MatteoPiscaglia, MarcoMorena, ValentinaGiacomelli, AndreaFalvella, StefaniaCossu, Maria VittoriaCapetti, Amedeo F + Article (author) -
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 2020 D'Arminio Monforte A.Passerini S.Perno C. F.Galli M.Lazzarin A.Marchetti G. C.D'Arminio Monforte A.Perno C. F.Bai F.Balotta C.Bandera A.Capetti A.D'Arminio Monforte A.Gori A.Lapadula G.Perno C. F.Rossotti R.Rusconi S.Santoro M. M.MacChia M.Carrara S.D'Arminio Monforte A.Galli M.Lazzarin A.Cannizzo E. S.Moioli M. C.Piolini R.Bernacchia D.Tincati C. + Article (author) -
Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? 2020 Antinori S.Bonazzetti C.Capetti A.Morena V.Rimoldi S.Sarzi-Puttini P. + Article (author) -
Cohort profile : The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 2019 Capetti, AmedeoCossu, Maria VittoriaGiacomelli, AndreaRusconi, Stefano + Article (author) -
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents 2019 Giacomet, VaniaCossu, Maria V.Capetti, Amedeo F.Zuccotti, Gian Vincenzo + Article (author) -
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study 2019 Capetti, ARusconi, SGiacomelli, A + Article (author) -
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study 2019 Rusconi, StefanoCossu, Maria VittoriaGiacomelli, AndreaCapetti, Amedeo + Article (author) -
Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients 2019 Rusconi, StefanoCapetti, AmedeoCossu, Maria Vittoria + Article (author) -
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 2018 Capetti A.Gismondo M. R.Cicconi P.Rusconi S.Micheli V. + Article (author) -
Dolutegravir plus rilpivirine as a switch option in cART-experienced patients : 96-week data 2018 Capetti, Amedeo FerdinandoCossu, Maria VittoriaRusconi, Stefano + Article (author) -
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 2018 Capetti ARusconi SGiacomelli ACOSSU, MARIA VITTORIA + Article (author) -
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 2017 Capetti A.Rusconi S.Cossu M. V. + Article (author) -
Effects of ritonavir and cobicistat on dolutegravir exposure : when the booster can make the difference 2017 A. RivaV. CozziA.F. CapettiE.G.I. Clementi + Article (author) -